Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
REGULATORY
Japan Cancels Purchase of 40 Million AstraZeneca Shots: Official
The Japanese government has canceled an order of 40 million COVID-19 vaccine doses from AstraZeneca, which constitute one-third of what it agreed to purchase in its supply pact inked in 2020, a health ministry official revealed on April 11. Yasuyuki…
To read the full story
Related Article
- Japan Ends Supply of AstraZeneca’s COVID Jab, 13.5 Million Doses Discarded
October 3, 2022
- Japan Can Get Refund on AstraZeneca Vaccine Cancellation: Minister
April 14, 2022
- AstraZeneca Vaccine OK’ed for Age 40 and Up under Emergency Program
August 2, 2021
- PMDA Review Report: Flexible Discussions Needed for Eligibility of AstraZeneca Vaccine
May 24, 2021
- Japan Approves Moderna and AstraZeneca COVID-19 Vaccines
May 21, 2021
- AstraZeneca, Moderna COVID-19 Vaccines in Line for Japan Approval on May 21
May 21, 2021
- AstraZeneca, Moderna COVID-19 Vaccines Up for Key Panel Review on May 20
May 17, 2021
- Takeda Submits NDA for Moderna Vaccine in Japan
March 5, 2021
- Health Minister Hails Domestic Production Plan for AstraZeneca Vaccine
February 8, 2021
- AstraZeneca Files COVID-19 Vaccine in Japan
February 5, 2021
- AstraZeneca, Japan Govt Ink Definitive Deal on COVID-19 Vaccine
December 11, 2020
- Japan to Earmark 671.4 Billion Yen to Secure Coronavirus Vaccines, Anticipating Final Agreements with 3 Companies
September 9, 2020
- AstraZeneca Launches Japan PI/II Study of COVID-19 Vaccine; Submission Could Be Possible Based on Results
September 7, 2020
- AstraZeneca to Supply 120 Million Doses of COVID-19 Vaccine to Japan
August 11, 2020
- Pfizer to Supply COVID-19 Vaccine Doses for 60 Million People in Japan
August 3, 2020
- JCR in Talks with AstraZeneca on COVID-19 Vaccine Solution Manufacturing
August 3, 2020
- AstraZeneca Aims to Deliver100 Million Doses of Coronavirus Vaccine to Japan: CEO
July 21, 2020
- Specific Vaccine Negotiations with AstraZeneca about to Start: Minister
July 1, 2020
- AstraZeneca in Talks with Daiichi Sankyo, Meiji Group on COVID-19 Vaccine Supplies in Japan
June 29, 2020
REGULATORY
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
- Gist of FY2025 Drug Price Revision
December 26, 2024
- Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
- DPP’s Tamaki Rails Against Govt’s Price Revision Decision
December 26, 2024
- Japan Doles Out Orphan Tags for Nihon Servier’s Vorasidenib, 11 More APIs
December 26, 2024
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…